hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial…more
hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial…more
Latest RNS from hVIVO plc
- Appointment of Chief Financial Officer
- board_changeBoard Changes
- interim_resultsInterim Results
- board_changeChief Financial Officer Succession
- acquisitionhVIVO acquires CRS Berlin
Analyst consensus: Buy
As of 23 Oct 2026, 7 analysts rate hVIVO plc a Buy, with 71% buy ratings and a mean price target of 16p (range 10p–25p), +184% vs the current price.